Industry News
Biotechnology Industry News
Fierce Biotech Layoff Tracker: Kaleido closes up shop, Akebia cuts 42% of workforce
Fierce Biotech Layoff Tracker: Kaleido closes up shop, Akebia cuts 42% of workforce aarmstrong Thu, 03/31/2022 - 16:21
Fierce Biotech Layoff Tracker: ProQR ousts 30% of staff after phase 2/3 setback, cuts across medtech
Fierce Biotech Layoff Tracker: ProQR ousts 30% of staff after phase 2/3 setback, cuts across medtech aarmstrong Thu, 03/31/2022 - 16:21
Fierce Biotech Layoff Tracker: Layoffs hit small biotechs Finch, Imara
Fierce Biotech Layoff Tracker: Layoffs hit small biotechs Finch, Imara aarmstrong Thu, 03/31/2022 - 16:21
Fierce Biotech Layoff Tracker: Judgement day for Nektar; SolidBio makes cuts
Fierce Biotech Layoff Tracker: Judgement day for Nektar; SolidBio makes cuts aarmstrong Thu, 03/31/2022 - 16:21
Fierce Biotech Layoff Tracker: Spero cuts workforce after tough FDA call, Genocea crumbles
Fierce Biotech Layoff Tracker: Spero cuts workforce after tough FDA call, Genocea crumbles aarmstrong Thu, 03/31/2022 - 16:21
Fierce Biotech Layoff Tracker: Agios slims R&D operations, Spero cuts after tough FDA call
Fierce Biotech Layoff Tracker: Agios slims R&D operations, Spero cuts after tough FDA call aarmstrong Thu, 03/31/2022 - 16:21
Fierce Biotech Layoff Tracker: Agios slims R&D operations, Scholar Rock in a hard place
Fierce Biotech Layoff Tracker: Agios slims R&D operations, Scholar Rock in a hard place aarmstrong Thu, 03/31/2022 - 16:21
Fierce Biotech Layoff Tracker: Genocea closes up shop, Applied axes 40% of staff
Fierce Biotech Layoff Tracker: Genocea closes up shop, Applied axes 40% of staff aarmstrong Thu, 03/31/2022 - 16:21
Fierce Biotech Layoff Tracker: Atreca culls workforce in reorganization; Genocea closes up shop
Fierce Biotech Layoff Tracker: Atreca culls workforce in reorganization; Genocea closes up shop aarmstrong Thu, 03/31/2022 - 16:21
Chutes & Ladders—John Mascola departs NIAID’s Vaccine Research Center after 22 years
Chutes & Ladders—John Mascola departs NIAID's Vaccine Research Center after 22 years mbayer Thu, 03/31/2022 - 14:34
Vertex gets proof-of-concept for non-opioid painkiller, clearing way for pivotal studies
Vertex gets proof-of-concept for non-opioid painkiller, clearing way for pivotal studies aarmstrong Thu, 03/31/2022 - 10:59
Reuniting the band: Former Merck CEO follows 3 former colleagues to Eikon
Reuniting the band: Former Merck CEO follows 3 former colleagues to Eikon mbayer Thu, 03/31/2022 - 09:38
Taysha lays off 35% of staff, narrows R&D focus to keep funding its top gene therapies
Taysha lays off 35% of staff, narrows R&D focus to keep funding its top gene therapies ntaylor Thu, 03/31/2022 - 08:00
Ono pulls trigger on deal for multispecific antibody against ‘very challenging’ cancer target
Ono pulls trigger on deal for multispecific antibody against 'very challenging' cancer target ntaylor Thu, 03/31/2022 - 06:39
CytoDyn’s leronlimab slapped with FDA holds for COVID-19, HIV programs
CytoDyn's leronlimab slapped with FDA holds for COVID-19, HIV programs aarmstrong Wed, 03/30/2022 - 17:50
UPDATE: After FDA hold, CytoDyn will appeal for pharma partnerships to save leronlimab
UPDATE: After FDA hold, CytoDyn will appeal for pharma partnerships to save leronlimab aarmstrong Wed, 03/30/2022 - 17:50
An FDA panel reviewing Amylyx’s ALS drug was moved by patient testimony—but they voted it down anyway
An FDA panel reviewing Amylyx's ALS drug was moved by patient testimony—but they voted it down anyway aarmstrong Wed, 03/30/2022 - 16:26
2 gene editing biotechs team up to improve on delivery with $45 upfront
2 gene editing biotechs team up to improve on delivery with $45 upfront gmasson Wed, 03/30/2022 - 16:08
2 gene editing biotechs team up to improve on delivery with $45M upfront
2 gene editing biotechs team up to improve on delivery with $45M upfront gmasson Wed, 03/30/2022 - 16:08
EU regulators warn clinical trial changes ‘unavoidable’ in Ukraine due to Russian invasion
EU regulators warn clinical trial changes 'unavoidable' in Ukraine due to Russian invasion gmasson Wed, 03/30/2022 - 14:34